Zusammenfassung
Die retinale angiomatöse Proliferation (RAP) ist eine Unterform der exsudativen altersabhängigen Makuladegeneration, die sich durch einen intraretinalen Ursprung der Läsionen auszeichnet und eine besonders schlechte Prognose aufweist. In diese retrospektive Fallserie wurden 33 Augen von 33 Patienten mit RAP-Läsionen im Stadium III eingeschlossen und initial mit 3 intravitrealen Eingaben von 0,5 mg Ranibizumab in monatlichen Abständen behandelt. Kriterien für eine Weiterbehandlung waren Visusminderung, frische Blutungen, Restflüssigkeit oder Zunahme der zentralen Netzhautdicke im OCT sowie persistierende Aktivität in der Fluoreszenzangiographie (FLA). Der Nachbeobachtungszeitraum betrug 8 Monate. Der mittlere „best corrected visual acuity“ (BCVA) stieg von logMAR 0,71 zum Ausgangszeitpunkt nicht signifikant auf logMAR 0,67 nach den ersten 3 intravitrealen Behandlungen an und blieb stabil bei logMAR 0,67 nach 8 Monaten. Die mittlere Abnahme der zentralen Netzhautdicke nach 4 Monaten (–90 μm) und nach 8 Monaten (–70 μm) war signifikant. Von den eingeschlossenen Patienten wurden 67% mehrfach wiederbehandelt, die mittlere Frequenz an Reinjektionen betrug 2,27 Injektionen nach 8 Monaten. Die intravitreale Eingabe von Ranibizumab führt bei Patienten mit RAP-Läsionen im Stadium III zu funktioneller und anatomischer Stabilisierung. In den meisten Fällen ist eine wiederholte Behandlung notwendig. Dies untermauert den dringenden Bedarf einer engmaschigen Nachkontrolle.
Abstract
Retinal angiomatous proliferation (RAP) is a subtype of exudative age-related macular degeneration which is characterized by an intraretinal origin of the lesion and a particularly poor prognosis. In this retrospective case study 33 eyes from 33 patients with stage III RAP lesions were included and initially treated with 3 intravitreal injections of 0.5 mg ranibizumab at monthly intervals. Criteria for extended treatment were visual deterioration, fresh bleeding, residual fluid or increase of the central retinal thickness in optical coherence tomography (OCT) as well as persisting activity in fluorescence angiography (FLA). The follow-up period was 8 months. The mean best corrected visual acuity (BCVA) increased insignificantly from logMAR 0.71 at the start of therapy to logMAR 0.67 after the first 3 intravitreal treatment injections and remained stable up to 8 months. The mean decrease of the central retinal thickness after 4 months (-90 µm) and after 8 months (-70 µm) was significant. Of the patients included in the study 67 % were treated repeatedly and the mean frequency of reinjections was 2.27 injections after 8 months. The intravitreal injection of ranibizumab in patients with stage III RAP lesions resulted in functional and anatomical stabilization. In most cases repeated treatment is necessary which underlines the urgent need for close surveillance in follow-up
Literatur
Kellner U, Wachtlin J (2008) Retina, 1 Aufl. Thieme, Stuttgart
Yannuzzi LA, Freund KB, Takahashi BS (2008) Review of retinal angiomatous proliferation or type 3 neovascularization. Retina 28(3):375–384
Yannuzzi LA et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21(5):416–434
Gass JDM, Agarwal A, Lavina AM et al (2003) Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal anastomosis. Retina 23:241–251
Marticorena J et al (2011) Retinal angiomatous proliferation. Curr Drug Targets 12(2):199–205
Krebs I et al (2007) Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 245(3):376–384
Krebs I et al (2008) Subretinal surgery and transplantation of autologous pigment epithelial cells in retinal angiomatous proliferation. Acta Ophthalmol 86(5):504–509
Reche-Frutos J et al (2011) Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome. Eur J Ophthalmol 21(6):783–788
Viola F et al (2009) Retinal angiomatous proliferation: natural history and progression of visual loss. Retina 29(6):732–739
Krebs I et al (2009) Retinal angiomatous proliferation: morphological changes assessed by Stratus and Cirrus OCT. Ophthalmic Surg Lasers Imaging 40(3):285–289
Politoa A et al (2006) The role of optical coherence tomography (OCT) in the diagnosis and management of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration. Ann Acad Med Singapore 35(6):420–424
Mendrinos E, Petropoulos IK, Pournaras CJ (2009) Retinal angiomatous proliferations: When should we suspect them and how should we detect them? Klin Monatsbl Augenheilkd 226(4):284–288
Scott AW, Bressler SB (2010) Retinal angiomatous proliferation or retinal anastomosis to the lesion. Eye (Lond) 24(3):491–496
Heimann H, Kellner U (2010) Atlas des Augenhintergrunds, 1 Aufl. Thieme, Stuttgart
Gross NE et al (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25(6):713–718
Gupta B, Jyothi S, Sivaprasad S (2010) Current treatment options for retinal angiomatous proliferans (RAP). Br J Ophthalmol 94(6):672–677
Koizumi H et al (2008) Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol 246(4):515–520
Berufsverband der Augenärzte Deutschlands e.V., D.O.G. e.V., Retinologische Gesellschaft (2007) Stellungsnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd 224(7):559–566
Rosenfeld PJ et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431
Lalwani GA et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43–58
Regillo CD et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145(2):239–248
Folk JC, Stone EM (2010) Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 363(17):1648–1655
Berufsverband der Augenärzte Deutschlands e.V., D.O.G. e.V., Retinologische Gesellschaft (2005) Empfehlung für die Durchführung von intravitrealen Injektionen (IVI). Klin Monatsbl Augenheilkd 222(5):390–395
George S, Cooke C, Chakravarthy U (2010) Exudative AMD subtypes and eligibility for treatment with ranibizumab. Eye (Lond) 24(7):1247–1251
Konstantinidis L et al (2009) Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 247(9):1165–1171
Kramann CA et al (2010) Intravitreal ranibizumab treatment of retinal angiomatous proliferation. Acta Ophthalmol 90(5):487–491
Lai TY et al (2007) Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245(12):1877–1880
Lommatzsch A et al (2010) Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy. Ophthalmologe 108(3):244–251
Atmani K et al (2010) Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye (Lond) 24(7):1193–1198
Rouvas AA et al (2009) Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina 29(4):536–544
Boscia F et al (2005) Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation. Eur J Ophthalmol 15(4):513–516
Boscia F et al (2004) Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 138(6):1077–1079
Shimada H et al (2005) Surgical excision of neovascularization in retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 243(6):519–524
Shiragami C et al (2007) Recurrence after surgical ablation for retinal angiomatous proliferation. Retina 27(2):198–203
Parodi MB et al (2011) Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol [Epub ahead of print]
Wolf A et al (2008) Anti-VEGF treatment for retinal angiomatous proliferation. Ophthalmologe 105(9):845–851
Kang JH et al (2007) Retinal angiomatous proliferation and intravitreal bevacizumab injection. Korean J Ophthalmol 21(4):213–215
Montero JA et al (2009) Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III. Eur J Ophthalmol 19(3):448–451
Freund KB et al (2006) Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 124(4):487–492
Krebs I et al (2008) Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol 246(2):237–243
Lee MY, Kim KS, Lee WK (2011) Combination therapy of ranibizumab and photodynamic therapy for retinal angiomatous proliferation with serous pigment epithelial detachment in Korean patients: twelve-month results. Retina 31(1):65–73
Lo Giudice G et al (2009) Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation. Retina 29(7):949–955
Mantel I, Ambresin A, Zografos L (2006) Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol 16(5):705–710
Montero JA et al (2009) Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatous proliferation. Br J Ophthalmol 93(2):166–170
Nicolo M et al (2006) Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 244(10):1336–1338
Reche-Frutos J et al (2007) Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy. Eur J Ophthalmol 17(6):979–982
Saito M et al (2010) Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 149(3):472–481
Saito M et al (2008) Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 146(6):935–941
Moere A van de et al (2007) Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone. Am J Ophthalmol 143(4):701–704
Viola F et al (2010) Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Eye (Lond) 24(8):1344–1351
Mahmood S et al (2009) Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review. Eye (Lond) 23(3):530–535
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maier, M., Perz, C., Bockmaier, J. et al. Therapie der retinalen angiomatösen Proliferation im Stadium III. Ophthalmologe 110, 1171–1178 (2013). https://doi.org/10.1007/s00347-012-2732-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-012-2732-7
Schlüsselwörter
- Exsudative altersabhängige Makuladegeneration
- Retinale angiomatöse Proliferation
- Anti-VEGF-Therapie
- Intravitreale Behandlung
- Optische Kohärenztomographie